Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07213609 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
A Phase 1 study of Neoplasms and Neoplasms, Colorectal, sponsored by GlaxoSmithKline.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 47
- Enrollment target
- 9
- Study locations
NCT07213609: Recruiting Phase 1 study of Neoplasms and Neoplasms, Colorectal, sponsored by GlaxoSmithKline.
NCT07213609 is a Phase 1 study of Neoplasms and Neoplasms, Colorectal that is actively recruiting participants, run by GlaxoSmithKline. The registered enrollment target is 47 participants, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (97% lower). The trial reports 9 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07213609, a Phase 1 study of Neoplasms and Neoplasms, Colorectal, is actively recruiting participants, sponsored by GlaxoSmithKline.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 47 participants
- Enrollment target
- 9
- Study locations
Study Summary
Solid tumours are abnormal lumps of tissue that can occur in different parts of the body. The tumours involved in this study have specific genetic characteristics that can make them more aggressive and challenging to treat. The study will test whether GSK5460025 alone or in combination (potential combinations may be included in future amendments to the protocol) with other anti-cancer agents can decrease tumor size, is safe, well-tolerated, and how the drug is processed in the body over time.
Conditions Studied
Interventions
- DRUG GSK5460025
Study Locations (9)
Other
- GSK Investigational Site - Chiba
- GSK Investigational Site - Osaka
- GSK Investigational Site - Tokyo
- GSK Investigational Site - Tokyo
Ontario
- GSK Investigational Site - Hamilton
- GSK Investigational Site - Toronto
Ohio
- GSK Investigational Site - Canton
Tennessee
- GSK Investigational Site - Nashville
Quebec
- GSK Investigational Site - Montreal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2025-10-20 |
| Est. Completion | 2028-10-27 |
| Phase | Phase 1 |
What NCT07213609 shows while recruiting
NCT07213609 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 47 participants, a relatively small participant target, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which GSK5460025 is the first listed.
NCT07213609 lists 9 locations in 5 states (Other, Ontario, Ohio).
Frequently Asked Questions
What is clinical trial NCT07213609 about?
NCT07213609 is a clinical study titled "A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors". Solid tumours are abnormal lumps of tissue that can occur in different parts of the body. The tumours involved in this study have specific genetic characteristics that can make them more aggressive and challenging to treat. The study will test whether GSK5460025 alone or in combination (potential co...
What is the current status of trial NCT07213609?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 47 participants. The study started on 2025-10-20. Estimated completion is 2028-10-27.
What conditions does trial NCT07213609 study?
This clinical trial studies the following conditions: Neoplasms, Neoplasms, Colorectal.
What interventions are being tested in trial NCT07213609?
The interventions under investigation include: GSK5460025 (DRUG).
Who is sponsoring clinical trial NCT07213609?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07213609 being conducted?
This trial has 9 study locations across Ohio, Tennessee, Ontario, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07213609's enrollment target sits among peer trials
47 109th of 158 higher than 47 of 158 other Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)
RECRUITING · Phase 1
-
A Study of GSK5764227 in Participants With. Advanced Solid Tumors (EMBOLD PanTumor-101)
RECRUITING · Phase 1
-
Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
RECRUITING · Phase 1
-
Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers
RECRUITING · Phase 1
-
Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03313011 · 47 participants
The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech
- NCT03467516 · 47 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma
- NCT03886662 · 47 participants · Phase 1
A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
- NCT04013802 · 47 participants · Phase 1
TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI